Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
Combining AI video collaboration, professional audio expertise, MDEP-ready development, and ODM+ integration to enable next-generation intelligent meeting spacesTAIPEI, June 4, 2026 /PRNewswire/ -- Primax Electronics...
Delivering the Ultimate AAA Gameplay Experience, Display Leader Introduces Three New QD-Mini LED Gaming MonitorsIRVINE, Calif., June 4, 2026 /PRNewswire/ -- TCL®, one of the world's...
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.02375 per common share for the period of June 1, 2026 to June 30, 2026, which is equal to $0.285 per common share on an annualized basis. The dividend will be paid on June 30, 2026 to shareholders of record as of the close of business on June 15, 2026.
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
PITTSBURGH, June 3, 2026 /PRNewswire/ -- Wesco International (NYSE: WCC), a leading provider of business-to-business distribution, logistics services and supply chain solutions, announces its inclusion...
Unified Technology from ePlus, NVIDIA and Cisco Provides a Self-Contained, Fast-Acting and Secure SolutionHERNDON, Va., June 3, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS:...
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2